Top Markets
#1 Islamic Coin Islamic Coin +152.40%
#2 Bitway Bitway +44.09%
#3 Starpower Starpower +38.95%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +32.28%
#5 aelf aelf +28.62%
#6 Pons Pons +26.42%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.23%
#8 SkyAI SkyAI +18.91%
#9 Ocean Protocol Ocean Protocol +17.25%
#10 Bedrock Bedrock +16.75%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Ulisse Biomed S.p.A. Ulisse Biomed S.p.A.

Ulisse Biomed S.p.A.

UBM
Rank in Stocks #29599
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Share Price
$0.93739396
Last synced: 2026-01-08
Market Cap
$20.44M
Change (1 day)
0.60%
Change (1 year)
-6.88%
Country
IT
Trade Ulisse Biomed S.p.A. (UBM)

Category

Healthcare
P/E ratio for Ulisse Biomed S.p.A. (UBM)
P/E ratio as of 2026 TTM: 0
According to Ulisse Biomed S.p.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Ulisse Biomed S.p.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.